Inherited sodium channelopathies: Models for acquired arrhythmias?

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 282, Issue 4 51-4, 2002, Pages

  Balser, Jeffrey R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLECAINIDE; LIDOCAINE; MEXILETINE; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT;

ARRHYTHMOGENESIS; BRADYCARDIA; BRUGADA SYNDROME; CHANNEL GATING; DISEASE MODEL; EDITORIAL; GENE MUTATION; GENETIC DISORDER; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HUMAN; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; QT INTERVAL;

EID: 0036087310     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00757.2001     Document Type: Editorial

References (45)

1. "Brugada" syndrome: Clinical data and suggested pathophysiological mechanism
2. Sodium "channelopathies" and sudden death: Must you be so sensitive?
3. SCN5A mutation (T1620M) causing Brugada syndrome exhibits different phenotypes when expressed in Xenopus oocytes and mammalian cells
4. Use-dependent blockers and exit rate of the last ion from the multi-ion pore of a K channel
5. Effects of flecainide in patients with new SCN5A mutation: Mutation-specific therapy for long-QT syndrome?
6. Molecular mechanism for an inherited cardiac arrhythmia
7. + channel mutation causing both long-QT and Brugada syndromes
8. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: A distinct clinical and electrocardiographic syndrome. A multicenter report
9. Cardiac ionic currents and acute ischemia: From channels to arrhythmias
10. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation
11. Lidocaine induces a slow inactivated state in rat skeletal muscle sodium channels
12. Mechanism of frequency-dependent inhibition of sodium currents in frog myelinated nerve by the lidocaine derivative GEA
13. Electrophysiological characterization of SCN5A mutations causing long QT (E1784K) and Brugada (R1512W and R1432G) syndromes
14. Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent
15. Mortality and morbidity in patients receiving encainide, flecainide, or placebo
16. Sodium channels need not open before they inactivate
17. Mēchanistic link between local anesthetic action and inactivation gating probed by outer pore mutations in the rat μ1 sodium channel
18. A revised view of cardiac sodium channel blockade in the long-QT syndrome
19. Electrophysiological properties and responses to simulated ischemia in cat ventricular myocytes of endocardial and epicardial origin
20. Sodium channel block produces opposite electrophysiological effects in canine ventricular epicardium and endocardium
21. Flecainide-induced arrhythmia in canine ventricular epicardium. Phase 2 reentry?
22. Dynamic rearrangement of the outer mouth of a K channel during gating
23. max and the transient outward current
24. Differences in the electrophysiological response of canine ventricular epicardium and endocardium to ischemia: Role of the transient outward current
25. A dynamic model of the cardiac ventricular action potential. II. Afterdepolarizations, triggered activity, and potentiation
26. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome
27. A structural rearrangement in the sodium channel pore linked to slow inactivation and use dependence
28. Reentrant and nonreentrant mechanisms contribute to arrhythmogenesis during early myocardial ischemia: Results using three-dimensional mapping
29. The elusive link between LQT3 and Brugada syndrome: The role of flecainide challenge
30. + currents in ventricular myocytes from the epicardial border zone of the infarcted heart
31. + channels by local anesthetics
32. + channels
33. Reentrant arrhythmias in the subacute infarction period. The proarrhythmic effect of flecainide acetate on functional reentrant circuits
34. Drug-induced J point elevation: A marker for genetic risk of sudden death or ECG curiosity?
35. Human SCN 5A gene mutations alter cardiac sodium channel kinetics and are associated with the Brugada syndrome
36. Slow inactivation of the sodium conductance in squid giant axons. Pronase resistance
37. Cardiac conduction defects associate with mutations in SCN 5A
38. + channel blockade and to increases in heart rate. Implications for gene-specific therapy
39. Sodium channel block with mexilitine is effective in reducing dispersion of repolarization and preventing torsade de pointes in LQT2 and LQT3 models of the long-QT syndrome
40. Sodium channel selectivity filter regulates antiarrhythmic drug binding
41. A sodium channel mutation causes isolated cardiac conduction disease
42. + channel
43. Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes
44. Enhanced sodium channel intermediate inactivation in Brugada syndrome
45. Actions of lidocaine on reentrant ventricular rhythms in the subacute myocardial infarction period in dogs